STONERIDGE INVESTMENT PARTNERS LLC
Position in SLS — SELLAS Life Sciences Group, Inc.
CIK 1108831
RADNOR, PA
Position in SLS
as of Mar 31, 2026
· filed May 6, 2026
Position Value
$85,814
-$145,388 QoQ
Shares Held
20,287
-66.9% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 84%
Shared 16%
None 0%
Common Shares in SLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026STONERIDGE INVESTMENT PARTNERS LLC holds $1,324,200 across 8 Biotechnology names. SLS ranks #5 (6.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZVRA |
Zevra Therapeutics, Inc.
|
32,788 | $305,584 | |
| 2 | DYN |
Dyne Therapeutics, Inc.
|
16,611 | $301,157 | |
| 3 | CAPR |
Capricor Therapeutics, Inc.
|
8,397 | $255,268 | |
| 4 | NAGE |
Niagen Bioscience, Inc.
|
50,641 | $223,326 | |
| 5 | SLS |
SELLAS Life Sciences Group, Inc.
This page
|
20,287 | $85,814 | |
| 6 | MDXG |
Mimedx Group, Inc.
|
17,932 | $70,831 | |
| 7 | PGEN |
Precigen, Inc.
|
16,126 | $62,407 | |
| 8 | LCTX |
Lineage Cell Therapeutics, Inc.
|
12,540 | $19,813 |
All Filings in SLS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $85,814 | 20,287 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $231,202 | 61,327 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $86,471 | 53,709 | Shares | Sole | 2025-10-31 | |
| No filing history on record for this holder in this stock. | ||||||